Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Latanoprost

    Virtual Booth

    Contact Supplier

    Latanoprost

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Xalatan (TN)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 173,807Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Triple Hair Starts Phase 3 Dosing for Male Androgenetic Alopecia
    Triple Hair Starts Phase 3 Dosing for Male Androgenetic Alopecia

    02 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-02/triple-hair-doses-first-patient-in-phase-iii-clinical-trial-in-canada-for-male-androgenic-alopecia

    PHARMIWEB
    02 Apr 2026
    Share Share
    Understanding Latanoprost API COA Parameters
    Understanding Latanoprost API COA Parameters

    08 Jan 2026

    // PRESS RELEASE

    https://www.centurypharma.com/understanding-latanoprost-api-coa-parameters/

    PRESS RELEASE
    08 Jan 2026
    Share Share
    Mankind Pharma’s Generics Latanoprost Receives Approval in US
    Mankind Pharma’s Generics Latanoprost Receives Approval in US

    17 Dec 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220360

    FDA
    17 Dec 2025
    Share Share
    Qlaris Develops Combo Therapy of QLS-111 With Latanoprost
    Qlaris Develops Combo Therapy of QLS-111 With Latanoprost

    11 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250611125298/en/Qlaris-Bio-Announces-Development-of-Fixed-Dose-Combination-Therapy-with-QLS111-and-Latanoprost-for-the-Treatment-of-Glaucoma

    BUSINESSWIRE
    11 Jun 2025
    Share Share
    Micro Labs`s Generics Latanoprost Receives Approval in US
    Micro Labs`s Generics Latanoprost Receives Approval in US

    14 Apr 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219306

    FDA
    14 Apr 2025
    Share Share
    Enforcement Report - Week of March 19, 2025
    Enforcement Report - Week of March 19, 2025

    19 Mar 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-19-2025-87488.pdf

    FDA
    19 Mar 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.